Biotechnology

With the hire of Abecma veteran Dr. Steven Bernstein, Liberate Bio signals its readiness to take its 'off-the-shelf' CAR-M therapy into the clinic.

Following a strategic merger and a $200M financing round, Yarrow Bioscience is advancing a novel drug for autoimmune thyroid disease. But can it disrupt a market dominated by incumbents?

A federal jury found investment firm RA Capital willfully misappropriated trade secrets from Yale, a stark reminder for investors of the risks of lax IP due diligence.

Promising early data for BBT001 suggests a potent combination of rapid relief and quarterly dosing, but can the biotech startup navigate the long road from pilot to production?

With its $2.2B acquisition of Forte, argenx adds a first-in-class antibody, FB102, expanding its Vision 2030 strategy to redefine autoimmune care.

A positive EMA opinion for Minoryx's NEZGLYAL offers the first-ever drug therapy for a fatal childhood disease, highlighting a key regulatory pathway.

Vir Biotechnology's CFO departs, triggering a 7% stock slide. Can interim chief Brent Sabatini, an internal veteran, steady the ship amid strategic shifts?

Radiopharm Theranostics secures crucial funding for its promising oncology pipeline, but a sharp stock drop reveals deep investor concerns about dilution.

Samsung Epis Holdings reports solid growth driven by its biosimilar portfolio, but the real story is its strategic pivot to next-gen cancer drugs and global expansion.

Ipsen's BOLD trial for biliary atresia failed, a blow to families. But in the data from this setback lies a critical roadmap for future research.

A Tokyo innovator just hit Nasdaq via a SPAC. Is its vertically integrated model the key to unlocking the $67B longevity market or just another biotech gamble?

With 14,000 new biotech jobs on the horizon, a new AI-powered lab coach aims to train the next generation of scientists, starting in underserved high schools.

A series of decisive legal victories in the U.S. and Europe has given food giant Danone a powerful grip on the future of a key gut health microbe.

A new partnership between Lilac Biosciences and Soin Neuroscience aims to end the guesswork in pain management with groundbreaking RNA biomarker research.

Taiwan's Jyong Biotech touts a global licensing strategy for its BPH drug, but a closer look reveals significant clinical setbacks and financial pressures.

A landmark study in Nature unveils a novel 'armored' cell therapy that neutralizes tumor defenses, showing remarkable efficacy in advanced liver cancer.

A Korean biotech is betting big on the U.S. market with its new GERD drug. A deal with manufacturer Bora Pharmaceuticals is the first step. Is it enough?

AcroCyte Therapeutics secures funding from the US government's 'DARPA for Health,' validating its unique organoid tech and signaling a strategic push to solve organ shortages.

With a billion people globally struggling with sleep apnea and CPAP compliance low, Incannex Healthcare is advancing its oral drug IHL-42X, now in a key Phase 2 study.